Delaying second Pfizer-BioNTech dose could leave cancer patients with insufficient immunity
More than half of cancer patients receiving a single dose of the Pfizer COVID-19 vaccine may be left with little protection against the virus, according to a new preprint from researchers at the Francis Crick Institute and King’s College London.